Tag: Campylobacter and Enterotoxigenic Escherichia coli
Immuron prepares for diarrhoea-focused clinical trial as US FDA lifts clinical hold
Immuron, an Australia-based biopharmaceutical company, is slated to move forward with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) following approval from the US Food and Drug Administration (FDA).
Featured Article
How growth capital is helping an Australian manufacturer go global
There’s a particular kind of ingenuity that flourishes in regional Australia. Away from the noise of major business centres, founders build companies that quietly become world leaders in their field, solving deep specialised problems that global markets didn’t know could be solved. Modra Technology, based in Warragul in regional Victoria, is one of those companies.
